12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GMC-252: Phase I started

Genmedica began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate oral GMC-252 in 18 healthy volunteers and 9 patients. Safety...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >